Profound Medical (PROF) Registration Filing summary

Company overview and business model

• Commercial-stage medical device company developing incision-free, image-guided ablation systems for diseased tissue using MRI and ultrasound technologies.

• Lead product, TULSA-PRO, enables precise, incision- and radiation-free ablation of prostate tissue, with regulatory clearances in the US, Canada, and Europe.

• TULSA-PRO targets a broad spectrum of prostate diseases, including cancer and benign prostatic hyperplasia, and is designed for use with existing MRI infrastructure.

• Sonalleve platform, primarily marketed outside North America, is approved for uterine fibroids and palliative pain from bone metastases, with ongoing exploration of additional indications.

• Employs a hybrid recurring revenue model in the US, combining one-time payments and per-patient charges, and a capital sales model in Europe and Asia.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for working capital, capital expenditures, and general corporate purposes.

• May allocate a portion of proceeds to potential acquisitions or investments in complementary businesses or technologies, though no current commitments exist.

• Pending use, proceeds will be invested in investment-grade, interest-bearing securities.

Risk factors and disclosures

• Investment involves significant risk; detailed risk factors are provided in the prospectus supplement and incorporated SEC filings.

• Risks include uncertainties in financial projections, regulatory developments, market acceptance, competition, and sufficiency of financial resources.

• Forward-looking statements are subject to known and unknown risks that may cause actual results to differ materially.